Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | LPL | P06858 | 12/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21382549 | 0.91 | KDM4E (0.43) | DRD2DRD4LPLLIPGROCK1 | |
| SCHEMBL24820904 | 0.88 | LPL (0.40) | DRD2DRD4LPLLIPGROCK1 | |
| SCHEMBL22202029 | 0.80 | DRD2 (0.41) | DRD2DRD4CA1CA2CA9 | |
| SCHEMBL20612387 | 0.80 | BRD9 (0.39) | LPLLIPGROCK1BACE1CA1 | |
| SCHEMBL30720809 | 0.80 | PARP10 (0.54) | — | |
| SCHEMBL1636716 | 0.80 | PARP10 (0.54) | — | |
| SCHEMBL595500 | 0.79 | LPL (0.38) | LPLLIPGROCK1BACE1CA1 | |
| SCHEMBL31222957 | 0.79 | LPL (0.38) | LPLLIPGROCK1BACE1CA1 | |
| SCHEMBL422134 | 0.79 | PDE3B (0.44) | CA9 | |
| SCHEMBL16817936 | 0.78 | HTR5A (0.40) | DRD4LPLLIPGBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696688-A1 | BENZO-FUSED RING COMPOUND INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
| US-20250368605-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2025-12-04 | — | — | US | disclosed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| EP-4547669-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-05-07 | — | — | EP | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| WO-2024213042-A1 | BENZO-FUSED RING COMPOUND INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| US-20180079720-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-03-22 | — | — | US | disclosed |
| WO-2017140669-A1 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | SANOFI (FR) | 2017-08-24 | — | — | WO | disclosed |
| US-20170233340-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2017-08-17 | — | — | US | disclosed |
| US-9714221-B1 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2017-07-25 | — | — | US | disclosed |
| WO-2014125410-A1 | N-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-08-21 | — | — | WO | disclosed |
| US-20140018380-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-01-16 | — | — | US | disclosed |
| US-20140018380-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-01-16 | — | — | US | disclosed |
| EP-2670746-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | Centaurus Biopharma Co., Ltd. (CN) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012103806-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012103806-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018380-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | GPR119, GPR88, GPR84 | DRD2 1364/4885DRD4 3367/4885LPL 483/4885 |
| US-20250368605-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | CYP19A1, ESR1, ESR2 | DRD2 1097/4885DRD4 1245/4885LPL 3242/4885 |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | DRD2 2682/4885DRD4 3715/4885LPL 1167/4885 |
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | DRD2 4871/4885DRD4 4883/4885LPL 4699/4885 |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | DRD2 4499/4885DRD4 4596/4885LPL 2977/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | DRD2 4499/4885DRD4 4596/4885LPL 2977/4885 |
| US-20180079720-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, ESR1, ESR2 | DRD2 1097/4885DRD4 1245/4885LPL 3242/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | DRD2 4499/4885DRD4 4596/4885LPL 2977/4885 |
| US-20170233340-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, ESR1, ESR2 | DRD2 1097/4885DRD4 1245/4885LPL 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.